Literature DB >> 20881304

Reduced choroidal neovascular membrane formation in cyclooxygenase-2 null mice.

Kasra A Rezaei1, Hassanain S Toma, Jiyang Cai, John S Penn, Paul Sternberg, Stephen J Kim.   

Abstract

PURPOSE: To assess the degree of laser-induced choroidal neovascular membrane formation in wild-type (WT) and COX-2 null mice and to measure vascular endothelial growth factor (VEGF), interleukin (IL)-1β, and tumor necrosis factor (TNF)-α levels in the retina and choroid.
METHODS: Four laser burns were placed in each eye of WT and COX-2 null mice to induce choroidal neovascularization. Fluorescein angiography (FA) was performed at 14 days, and retinal pigment epithelium-choroid-sclera (choroidal) flat mounts were prepared. The retina and choroid were isolated from WT and COX-2 null mice at 24, 72, and 168 hours after laser photocoagulation and from unlasered eyes and were tested for VEGF, IL-1β, and TNF-α.
RESULTS: COX-2 null mice demonstrated 58% (P = 0.001) and 48% (P = 0.001) reductions in CNV formation on FA and choroidal flat mounts, respectively, compared with WT mice. For unlasered mice, mean VEGF concentrations in the retina and choroid were 1.2 ± 0.42 pg/mg protein for WT but only 0.42 ± 0.2 pg/mg protein for COX-2 null mice (P < 0.05). After laser photocoagulation, WT mice showed significantly greater VEGF and IL-β expression in the retina and choroid by 168 hours (P < 0.05) and 72 hours (P < 0.05), respectively, compared with COX-2 null mice.
CONCLUSIONS: COX-2 null mice exhibited significantly less choroidal neovascular membrane formation associated with reduced expression of VEGF. The results of this study suggest that COX-2 modulates VEGF expression in CNV and implicates a potential therapeutic role for nonsteroidal anti-inflammatory drugs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20881304      PMCID: PMC3053102          DOI: 10.1167/iovs.10-6319

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  35 in total

1.  Cyclooxygenase-2 gene expression and regulation in human retinal pigment epithelial cells.

Authors:  M S Chin; C N Nagineni; L C Hooper; B Detrick; J J Hooks
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-09       Impact factor: 4.799

2.  Pathogenesis of laser-induced choroidal subretinal neovascularization.

Authors:  H Miller; B Miller; T Ishibashi; S J Ryan
Journal:  Invest Ophthalmol Vis Sci       Date:  1990-05       Impact factor: 4.799

3.  Quantitative image analysis of laser-induced choroidal neovascularization in rat.

Authors:  J L Edelman; M R Castro
Journal:  Exp Eye Res       Date:  2000-11       Impact factor: 3.467

4.  Improved assessment of laser-induced choroidal neovascularization.

Authors:  Hassanain S Toma; Joshua M Barnett; John S Penn; Stephen J Kim
Journal:  Microvasc Res       Date:  2010-06-08       Impact factor: 3.514

5.  Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization.

Authors:  Hans E Grossniklaus; Jun X Ling; Timothy M Wallace; Stefan Dithmar; Diane H Lawson; Cynthia Cohen; Victor M Elner; Susan G Elner; Paul Sternberg
Journal:  Mol Vis       Date:  2002-04-21       Impact factor: 2.367

6.  Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration.

Authors:  Hilary L Wilson; Daniel M Schwartz; Hilarey R F Bhatt; Charles E McCulloch; Jacque L Duncan
Journal:  Am J Ophthalmol       Date:  2004-04       Impact factor: 5.258

7.  Inhibition of cyclooxygenase-2, but not cyclooxygenase-1, reduces prostaglandin E2 secretion from diabetic rat retinas.

Authors:  Surya P Ayalasomayajula; Aniruddha C Amrite; Uday B Kompella
Journal:  Eur J Pharmacol       Date:  2004-09-13       Impact factor: 4.432

Review 8.  Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis.

Authors:  Stephen Gately; Robert Kerbel
Journal:  Prog Exp Tumor Res       Date:  2003

9.  Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model.

Authors:  Surya P Ayalasomayajula; Uday B Kompella
Journal:  Eur J Pharmacol       Date:  2003-01-05       Impact factor: 4.432

10.  Topical nepafenac inhibits ocular neovascularization.

Authors:  Kyoichi Takahashi; Yoshitsugu Saishin; Yumiko Saishin; Keisuke Mori; Akira Ando; Satoru Yamamoto; Yuji Oshima; Hiroyuki Nambu; Michele B Melia; David P Bingaman; Peter A Campochiaro
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-01       Impact factor: 4.799

View more
  10 in total

1.  The safety, pharmacokinetics, and efficacy of intraocular celecoxib.

Authors:  Stephen J Kim; Hassanain Toma; Rohan Shah; Uday B Kompella; Sunil K Vooturi; Jinsong Sheng
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-03-10       Impact factor: 4.799

2.  Novel Approaches for Retinal Drug and Gene Delivery.

Authors:  Stephen J Kim
Journal:  Transl Vis Sci Technol       Date:  2014-10-03       Impact factor: 3.283

3.  Effects of intravitreal bevacizumab (Avastin) on the porcine retina.

Authors:  Ianors Iandiev; Mike Francke; Felix Makarov; Margrit Hollborn; Susann Uhlmann; Antje Wurm; Alexey Savvinov; Leon Kohen; Andreas Reichenbach; Peter Wiedemann; Thomas Pannicke; Andreas Bringmann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-08-16       Impact factor: 3.117

4.  Anti-angiogenic effect of hexahydrocurcumin in rat corneal neovascularization.

Authors:  Chien-Neng Kuo; Ching-Hsein Chen; San-Ni Chen; Jou-Cheng Huang; Li-Ju Lai; Chien-Hsiung Lai; Chia-Hui Hung; Chien-Hsing Lee; Chung-Yi Chen
Journal:  Int Ophthalmol       Date:  2017-04-09       Impact factor: 2.031

5.  Targeted Imaging of VCAM-1 mRNA in a Mouse Model of Laser-Induced Choroidal Neovascularization Using Antisense Hairpin-DNA-Functionalized Gold-Nanoparticles.

Authors:  Md Imam Uddin; Tyler C Kilburn; Rong Yang; Gary W McCollum; David W Wright; John S Penn
Journal:  Mol Pharm       Date:  2018-10-29       Impact factor: 4.939

6.  Critical appraisal of ophthalmic ketorolac in treatment of pain and inflammation following cataract surgery.

Authors:  Rahul Reddy; Stephen Jae Kim
Journal:  Clin Ophthalmol       Date:  2011-06-03

7.  Protective effects of resveratrol against UVA-induced damage in ARPE19 cells.

Authors:  Chi-Ming Chan; Cheng-Hua Huang; Hsin-Ju Li; Chien-Yu Hsiao; Ching-Chieh Su; Pei-Lan Lee; Chi-Feng Hung
Journal:  Int J Mol Sci       Date:  2015-03-12       Impact factor: 5.923

8.  Osmotic induction of cyclooxygenase-2 in RPE cells: Stimulation of inflammasome activation.

Authors:  Luise Messerschmidt; Sarah Fischer; Peter Wiedemann; Andreas Bringmann; Margrit Hollborn
Journal:  Mol Vis       Date:  2019-06-30       Impact factor: 2.367

9.  Nonsteroidal anti-inflammatory drugs for retinal disease.

Authors:  Scott D Schoenberger; Stephen J Kim
Journal:  Int J Inflam       Date:  2013-01-14

10.  The COX-2-Selective Antagonist (NS-398) Inhibits Choroidal Neovascularization and Subretinal Fibrosis.

Authors:  Ruoshuang Zhang; Zheli Liu; Han Zhang; Yi Zhang; Dong Lin
Journal:  PLoS One       Date:  2016-01-13       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.